Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action

Lili Ma; Rong Ma; Yiping Wang; Xiaoyue Zhu; Junliang Zhang; Hoi Ching Chan; Xianfeng Chen; Wenjun Zhang; Sung-Kay Chiu; Guangyu Zhu

doi:10.1039/c4cc10409a

Author(s)

Lili Ma
Rong Ma
Yiping Wang
Xiaoyue Zhu
Junliang Zhang
Hoi Ching Chan
Xianfeng Chen
Sung-Kay Chiu

Related Research Unit(s)

Detail(s)

Original language	English
Pages (from-to)	6301-6304
Journal / Publication	Chemical Communications
Volume	51
Issue number	29
Online published	27 Jan 2015
Publication status	Published - 14 Apr 2015

Link(s)

DOI	DOI https://doi.org/10.1039/c4cc10409a Final Published version
	Check@CityULib
Link to Scopus	https://www.scopus.com/record/display.uri?eid=2-s2.0-84925967704&origin=recordpage
Permanent Link	https://scholars.cityu.edu.hk/en/publications/publication(992db087-c43b-451c-b619-4015ef69e4e7).html

Abstract

Complexation of cisplatin with a p53 activator as a single anticancer agent resulted in synergistically improved cytotoxicity in p53 wild-type but not p53 null human cancer cells. Mechanistic investigation was carried out on this dual-targeting Pt(iv) prodrug, chalcoplatin. The prodrug effectively entered cancer cells and arrested the cell cycle at the S and G₂/M phases, distinctive of that from cisplatin. Chalcoplatin significantly induced p53 activation as well as the subsequent apoptosis pathways. This unique mode of action renders chalcoplatin remarkably cytotoxic and makes this compound among the first examples of a Pt(iv) prodrug that directly interacts with the downstream pathway after the formation of Pt-DNA lesions. This journal is

Citation Format(s)

[ RIS ] [ BibTeX ]

Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action. / Ma, Lili; Ma, Rong; Wang, Yiping et al.

In: Chemical Communications, Vol. 51, No. 29, 14.04.2015, p. 6301-6304.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62) › 21_Publication in refereed journal › peer-review

Ma, L, Ma, R, Wang, Y, Zhu, X, Zhang, J, Chan, HC, Chen, X, Zhang, W, Chiu, S-K & Zhu, G 2015, 'Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action', Chemical Communications, vol. 51, no. 29, pp. 6301-6304. https://doi.org/10.1039/c4cc10409a

Ma, L., Ma, R., Wang, Y., Zhu, X., Zhang, J., Chan, H. C., Chen, X., Zhang, W., Chiu, S-K., & Zhu, G. (2015). Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action. Chemical Communications, 51(29), 6301-6304. https://doi.org/10.1039/c4cc10409a

Ma L, Ma R, Wang Y, Zhu X, Zhang J, Chan HC et al. Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action. Chemical Communications. 2015 Apr 14;51(29):6301-6304. Epub 2015 Jan 27. doi: 10.1039/c4cc10409a

Ma, Lili ; Ma, Rong ; Wang, Yiping et al. / Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action. In: Chemical Communications. 2015 ; Vol. 51, No. 29. pp. 6301-6304.